Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 54.00
Ask: 55.00
Change: 1.20 (2.18%)
Spread: 1.00 (1.852%)
Open: 54.50
High: 56.20
Low: 54.00
Prev. Close: 55.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Formation of Cantab Corporate Health Limited

21 Sep 2015 07:00

RNS Number : 5678Z
Cambridge Cognition Holdings PLC
21 September 2015
 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Cambridge Cognition forms Cantab Corporate Health Limited

 

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces it has entered into an agreement with Shandwell Ltd ('Shandwell') to launch Cantab Corporate Health Limited ('CCHL') and that CCHL has secured its first contract.

 

CCHL will be dedicated to working with employers and their healthcare providers in delivering sensitive and accurate cognitive assessments in all relevant workplace settings using the proprietary CANTAB™ tests from Cambridge Cognition. The tests are run through iPads and provide reports in minutes, helping identify problems which can then be managed in the workplace. CCHL's business development will be managed by Shandwell, a consultancy business specialising in improving the health and wellbeing of the working population, in return for a minority equity stake in the new entity.

 

CCHL will deliver a new revenue stream to Cambridge Cognition through licensing revenues, royalties and product sales, and it will create a vehicle to access the growing global corporate sector that isn't targeted by the Company's current marketing channels.

 

Occupational health is a very significant near term opportunity. Managing the associated risks of cognitive health is now on the international employer agenda with new initiatives such as The Alzheimer's Society guide for dementia friendly employers. Over 1.3m UK employees now work for employers signed up to the Charter of Employers who are positive about mental health. These trends translate to a UK market, for work related cognitive health assessments, which the Directors estimate to be worth in excess of £26m per annum.

 

Significantly, CCHL has already signed its first contract with a UK provider whose clients include some of the world's leading employers.

 

Dr Steven Powell, Cambridge Cognition's Chief Operating Officer, said: "With an ageing working population, there is an increasing need to manage the associated cognitive health risks. Our technology is being used widely in primary care, research and pharmaceutical development. This new venture with Shandwell, which has an excellent track record of introducing innovation into the corporate health and wellbeing sector, will demonstrate the benefits of our products on an even wider scale."

 

John Picken, Managing Director, of Shandwell said: "There is a growing understanding that cognitive health determines what work we can do and for how long. Closely linked to physical health, it also has a significant impact on performance and productivity. This new venture will give all stakeholders in the health of the working population the opportunity to measure and help manage cognitive health using the latest digital health tools. The tests are culturally neutral, language independent and applicable across all ages and in all occupations from the shop floor to the boardroom. We already have a strong interest for our offer in the UK and considerable global interest."

 

For further information visit www.cantabcorp.com 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

 

 

 

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303

Paul McManus

Mob: 07980 541 893

   

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

 

 

About Shandwell Ltd

Shandwell was established in 2008 by John Picken, ex CEO of Third Party Health Administrator, Medisure. Specialising in improving the health and wellbeing of the working population, it has worked on projects with employers, healthcare providers and government agencies. It has been responsible for developing new and award winning propositions, including managing the key health risks of cancer and obesity. Just prior to forming Cantab Corporate Health with Cambridge Cognition, Shandwell supported a group of some of the world's leading neurologists.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFMFLAFISEFU
Date   Source Headline
21st Mar 20247:00 amRNSFormation of new Scientific Advisory Board
21st Feb 202410:16 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSCambridge Cognition and ActiGraph Partnership
30th Jan 20244:20 pmRNSDirector/PDMR Share Purchases
30th Jan 20247:00 amRNSBoard appointments
30th Jan 20247:00 amRNSTrading Update
18th Dec 20237:00 amRNSGrant of Options
1st Dec 20237:00 amRNSTotal Voting Rights
22nd Nov 20237:00 amRNSChange of Auditor
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20237:00 amRNSAutomated quality assurance for clinical trials
11th Oct 20237:00 amRNSMajor contract win combining solutions
5th Oct 20235:33 pmRNSIssue of Warrants
3rd Oct 20232:43 pmRNSBlock listing Interim Review
28th Sep 20233:35 pmRNSHolding(s) in Company
26th Sep 20237:01 amRNSInterim Results
26th Sep 20237:00 amRNSSecured £3 million Term Loan
4th Sep 20237:00 amRNSNotice of Interim Results
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20234:26 pmRNSResult of AGM
13th Jun 20237:00 amRNS£2m contract for a pivotal cancer therapy trial
9th Jun 20237:00 amRNSNotice of AGM – Revision to Explanatory Note
6th Jun 20237:00 amRNSPosting of Annual Report & Notice of AGM
31st May 20237:00 amRNSCapital Markets Day
3rd May 20237:00 amRNSResults for the year ended 31 December 2022
26th Apr 20237:00 amRNSInvestor Webinar and Analyst Briefing
20th Apr 20237:00 amRNSNotice of Results
12th Apr 20237:00 amRNS£2.1 million contracts for rare disease trials
21st Mar 20237:00 amRNSBlock Admission Application & Exercise of Options
6th Feb 20237:00 amRNSDirector/PDMR Share Purchases
31st Jan 20237:00 amRNSTrading Update
30th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 202312:22 pmRNSHolding(s) in Company
17th Jan 20235:54 pmRNSHolding(s) in Company
17th Jan 20234:06 pmRNSHolding(s) in Company
13th Jan 20235:09 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSAcquisition of Winterlight Labs Inc
24th Nov 20227:00 amRNSStrategic Partnership for Chinese Market Expansion
19th Oct 20227:00 amRNS£1.1 million eCOA contract win
12th Oct 20227:00 amRNSAcquisition of eClinicalHealth Limited
20th Sep 20227:00 amRNSInterim Results
1st Sep 20227:00 amRNS£2.2m neurodegenerative disease trial contract
17th Aug 20227:00 amRNSAlzheimer’s Disease Validation for NeuroVocalix
3rd Aug 20222:55 pmRNSDirectorate Change
28th Jul 20227:00 amRNSPTSD trials with top 10 pharma company & US DoD
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSDirector/PDMR Share Purchases

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.